Mymetics (Mymetics) Momentum Rank : 0 (As of May. 28, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Mymetics Momentum Rank?

Mymetics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Mymetics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Mymetics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Mymetics (Mymetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066

Website

https://www.mymetics.com

Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.

Executives

Marcel B. Ruegg	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard	officer: President, CEO, CFO	ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering	director, officer: President and CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin	officer: CEO	40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann	officer: CSO	KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern	director	815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin	director	POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury	officer: CSO	CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd.	10 percent owner	C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd	10 percent owner	ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet	director, officer: CEO	14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer	director, officer: vp corp development
Ernst Lubke	director, officer: CFO	39, ROUTE D'ARZIER, ARZIER V8 CH-1273